argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 45.55B +8.3% |
| Revenue (ttm) | 4.65B +70.3% |
| Net Income | 1.50B +33.9% |
| EPS | 22.95 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 31.75 |
| Forward PE | 24.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,853 |
| Open | 733.80 |
| Previous Close | 705.60 |
| Day's Range | 719.20 - 745.60 |
| 52-Week Range | 568.40 - 925.00 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 1,013.75 (+39.18%) |
| Earnings Date | Oct 22, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is €1,014, which is an increase of 39.18% from the latest price.
News
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintained by Baird -- Price Target Lowered to $823
ARGX Maintained by Baird -- Price Target Lowered to $823
Argenx price target lowered to $1,140 from $1,250 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Argenx (ARGX) to $1,140 from $1,250 and keeps an Overweight rating on the shares after the company discontinued the Phase 3 UNITY…
Argenx price target lowered to $1,078 from $1,175 at Evercore ISI
Evercore ISI lowered the firm’s price target on Argenx (ARGX) to $1,078 from $1,175 and keeps an Outperform rating on the shares.
Argenx price target lowered to $823 from $932 at Baird
Baird analyst Collen Kusy lowered the firm’s price target on Argenx (ARGX) to $823 from $932 and keeps a Neutral rating on the shares. The firm updated its model following…
Argenx price target lowered to $1,355 from $1,415 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Argenx (ARGX) to $1,355 from $1,415 and keeps an Overweight rating on the shares. The firm says Sjogren’s disease…
First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo
Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps an Overweight rating on the shares. With Teva (TEVA) and Argenx (ARGX)…
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
argenx (ARGX) Reports Mixed Clinical Trial Results, Shares Drop 14%
argenx (ARGX) Reports Mixed Clinical Trial Results, Shares Drop 14%
Argenx has ‘good news and bad news’ day, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Argenx (ARGX) is having a “good news and bad news” day. The company announced positive topline results from the 126-patient Phase 2 FB102 study…
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.
argenx (ARGX) Shares Drop 14.2% Pre-Market Amid Market Uncertainty
argenx (ARGX) Shares Drop 14.2% Pre-Market Amid Market Uncertainty
argenx (ARGX) Shares Drop After Sjögren's Disease Trial Halt, Mixed Clinical Results
argenx (ARGX) Shares Drop After Sjögren's Disease Trial Halt, Mixed Clinical Results
Argenx Reports Mixed Pipeline Update With Positive Celiac Data; Ends Sjögren's Phase 3 Study
(RTTNews) - argenx SE (ARGX), a global immunology company, provided updates on two clinical programs, reporting positive Phase 2 results for FB102 in celiac disease while discontinuing the Phase 3 UNI...
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod drug in adults with Sjögren's disease, an autoimmune condition that damages the glands producing tears and saliva, ...
argenx (ARGX) Reports Positive Phase 2 Data for FB102 in Celiac Disease
argenx (ARGX) Reports Positive Phase 2 Data for FB102 in Celiac Disease
argenx (ARGX) Halts Phase 3 UNITY Trial for Sjogren's Disease Following IDMC Recommendation
argenx (ARGX) Halts Phase 3 UNITY Trial for Sjogren's Disease Following IDMC Recommendation
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Argenx to discontinue UNITY study of efgartigimod subcutaneous
Argenx (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous, or SC, in adults with moderate-to-severe Sjogren’s disease. The decision is based on the recommen...
Argenx announces FB102 study met its primary endpoint
Argenx (ARGX) announced topline results from the Phase 2 study evaluating FB102, a CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following...
Argenx's Celiac Disease Phase 2 Study Meets Primary Endpoint; Discontinues Sjögren's UNITY Trial
(RTTNews) - argenx SE (ARGX), an immunology company, on Thursday reported positive Phase 2 results for FB102 in celiac disease and separately announced that it will discontinue the Phase 3 UNITY study...
Argenx To Discontinue Phase 3 UNITY Study Of Efgartigimod In Sjgren's Disease
(RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. Following interim analysis, an ...
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study ...